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SARINGAN AKTIVITI ANTI-INFEKTIF DARI ORGANISMA MARIN DI 
MALAYSIA DENGAN MENGAPLIKASIKAN Caenorhabditis elegans 
SEBAGAI ORGANISMA MODEL 
 
ABSTRAK 
Kejadian rintangan antibiotik telah menjadi fenomena sering muncul yang belum 
ditemukan penawarnya. Penyelesaian alternatif untuk menghapuskan patogen boleh 
dilakukan melalui peningkatan sistem imun tuan rumah dan pengurangan virulensi 
patogen tanpa membunuh patogen dalam tuan rumah secara langung. Produk semula 
jadi sentiasa menjadi sumber utama untuk penemuan anti-infektif. Organisma marin 
merupakan sumber yang mempunyai entiti kima baru dengan aktiviti biologi. Dalam 
kajian ini, penyaringan anti-infektif 20 invertebrata marin dijalankan dengan 
menggunakan C. elegans sebagai perumah dan P. aeruginosa sebagai patogen. Hasil 
kajian menunjukkan estrak metanol Holothuria atra, lollyfish, dapat melangsungkan 
hidup C. elegans daripada jangkitan P. aeruginosa tanpa menjejaskan pertumbuhan 
bakteria dan pemakanan biasa perumah. Kebolehupayaan C. elegans untuk 
meningkatkan tahap gen lys-7 juga diperhatikan apabila diserangi jangkitan P. 
aerugniosa. H. atra telah dipilih untuk menjalankan pengasingan berpandukan bio-
asai and hasilnya, fraksi F3 dan F4 dapat melanjutkan jangka hayat C. elegans yang 
dijangkiti PA14. Kesan kedua-dua fraksi telah dicadangkan untuk bertindak terhadap 
faktor virulensi PA14 dan/atau meningkatkan sistem imun C. elegans menerusi 
laluan transduksi isyarat DAF2/DAF16. Analisis kimia F3 dan F4 menunjukkan 
bahawa kehadiran sebatian aspidospermatidine, EPA, alkaloid dan sebatian lain 
berpotensi untuk menjana akitiviti anti-infektif. Kesimpulannya, F3 dan F4 dari H. 
atra mengandungi sebatian anti-infektif yang dapat menyelamatkan C. elegans 
xv 
 
terhadap jangkitan P. aeruginosa dengan menggunakan kesan gabungan dalam 
peningkatan sistem imun perumah dan juga pengurangan virulensi patogen.      
 
SCREENING OF ANTI INFECTIVES FROM MALAYSIAN MARINE 
ORGANISMS USING Caenorhabditis elegans AS MODEL ORGANISM 
 
ABSTRACT 
Antibiotic resistance has been a reoccurring phenomenon that has yet to find an 
effective cure. There are alternatives in eliminating pathogens through increasing 
hosts’ immune system and reducing pathogen virulence without directly killing the 
pathogen in hosts. Natural products have always been the main sources of anti-
infective drugs. Marine organisms have been found to possess new chemical entities 
with potent biological activity. In this study, anti-infective activity of 20 marine 
invertebrates was screened using live-animal infection model, Caenorhabditis 
elegans-Pseudomonas aeruginosa host-pathogen screening assay. The results 
showed a methanolic crude extract of Holothuria atra, to double the survival of P. 
aeruginosa infected C. elegans without affecting both the bacteria growth and 
viability, as well as the normal feeding ability of the nematodes. An increase of lys-7 
expression was observed in the treated nematodes, indicating the secretion of innate 
immune response gene upon pathogen attack. Virulence factors of P. aeruginosa in 
C. elegans infection are also greatly reduced upon treatment Bioassay-guided 
fractionation was carried out on lollyfish, resulting in two semi-purified fractions (F3 
and F4) which produced positive results in all the assays. The effects of the active 
fractions have suggested to be acting on both the virulence factors of Pseudomonas 
aeruginosa and DAF2/DAF16 signalling pathway. Chemical analysis on F3 and F4 
indicated the co-existing constituents of aspidospermatidine, EPA and other alkaloids 
responsible for the activity. All in all, both F3 and F4 contained possible anti-
xvi 
 
infective molecules in improving the sustainability of C. elegans against P. 
aeruginosa infection by a combination effects on boosting up immunity of the host 
and attenuation of pathogen’s virulence factors.
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CHAPTER 1 
INTRODUCTION 
1.1 Research Background 
Antibiotic resistance has become so common that it affected both the 
prevention and treatment of infections caused by various pathogens (WHO, 2014). 
The phenomenon exists all over the world, indicating the desperate need to develop 
new anti-infective drugs in pharmaceutical industry (Tadesse et al., 2008). The 
frequent usage of traditional broad-spectrum antibiotics causes the emergence of not 
only resistant bacteria (Hoiby et al., 2001), but viruses (Mendes et al., 2011) and 
fungi (Chandra et al., 2001) as well. As direct killing of the pathogens do not serve 
much purpose nowadays due to the presence of antibiotic resistance, the main 
objective would be to find an alternative to combat the pathogen by reducing its 
virulence or by increasing hosts’ immune system, being termed as anti-infective in 
short (Smith et al., 2010).  
The novelty in mode of actions for the anti-infective drugs is vital, with 
targeted mechanism of action in pathogen killing. The development of novel anti-
infective drugs has been very much focused in pharmaceutical industry, especially 
incorporating natural produtcs. As the compounds isolated natural products give the 
best overall protective property to human, no doubt natural product have been and 
will continue to be the major player for drug development as there are higher hit rates 
on discovering active new chemical entities (NCE) from natural resources which are 
targeted on secondary metabolites in both terrestrial and marine organisms (Sarker et 
al., 2005). Plants and terrestrial animals have gone through investigations for anti-
bacterial, anti-fungal, anti-malarial compounds identification (Cowan, 1999), 
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whereas marine environment has been a huge untapped reservoir with possible rich 
source of anti-infective compounds in a variety of marine natural products which is 
pharmacologically important (Bhadury et al., 2006).  
The marine environment is so harsh yet diverse that the production of 
biologically active compounds by these marine organisms are found to have low 
scaffold similarities compared to those extracted from terrestrial organisms, and at 
the same time possess potent biological activity with targeted mechanism of actions. 
As such, scientists and researchers are keen to move towards the ocean for novel 
drug discovery as the new chemical entities obtained are novel with huge range of 
therapeutic properties (Newman and Cragg, 2007). With the latest technology and 
resources available, making use of marine natural products as the source of searching 
for potential anti-infective drugs has been a very promising journey, with 262 marine 
compounds currently in preclinical pharmaceutical pipeline (Mayer et al., 2013). 
The effectiveness of anti-infective agents is best determined with the host-
pathogen assay, where the impacts to both the host and pathogens can be detected 
simultaneously (Moy et al., 2006). With the increasing consciousness of animal 
welfare in scientific research, it is essential to search for model organisms to study 
the interactions. The nematode worm Caenorhabditis elegans is found to be the most 
suitable model organism for this particular purpose (Walhout et al., 1998). Despite 
being the simplest organism, the nematode is well-differentiated with muscle cells, 
hypodermis, a nervous system, gonads, intestine, glands and an excretory system in 
its 1mm long transparent body (Artal-Sanz et al., 2006). Besides, it has also been 
fully sequenced with 60-80% of genes orthologue to humans. Research have showed 
that the biochemical pathways of C. elegans and humans are high conserved; 
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allowing researchers to probe further in on biological drug effects as well as identify 
its molecular targets with this model organism (Culetto and Sattele, 2000).   
This study discusses the screening of anti-infectives found in marine 
invertebrates using a type of live-animal infection model, Caenorhabditis elegans-
Pseudomonas aeruginosa host-pathogen screening assay. The Gram-negative 
bacterium, Pseudomonas aeruginosa, is the common cause of nosocomial 
contamination in medical care facilities, causing hospital-acquired infections in 
mostly cystic fibrosis patients and immune-compromised patients (DiazGranados et 
al., 2009). The ability of P. aeruginosa to infect C. elegans has given an opportunity 
to venture into the possibility of pinpointing the effect of potential anti-infective 
compounds extracted to the host (Tan et al., 1999).   
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1.2 Aim of the study 
The increasing amount of incidents in multi-resistant pathogens have brought 
a huge negative impact on general public health and it is important to tackle the 
problem with an effective, fast and safe alternative to combat the pathogens by 
reducing its virulence or to counterstrike it by increasing hosts’ immune system. The 
untapped marine environment is definitely a good place to initiate the investigation 
on searching for novel active metabolites with anti-infective property. The aim of 
this present study was to identify the possible anti-infective compounds from marine 
natural products using Caenorhabditis elegans as a model system against 
Pseudomonas aeruginosa infection. 
This study is carried out to accomplish following objectives: 
i. To screen crude extracts of marine invertebrates from Northern Peninsular 
Malaysia costal waters for anti-infective activity. 
ii. To predict bioactive compounds with anti-infective properties from the selected 
marine organisms.  
iii. To determine the mode of action of the marine fractions on P. aeruginosa 
infected C.elegans.  
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CHAPTER 2 
LITERATURE REVIEW 
2.1 Antibiotic drug usage and resistance 
The use of antibiotics in humans has been made common since the 
introduction of penicillin in 1914 by Alexander Fleming. Since then, antibiotic is a 
life-saving medicine for those who are suffering from mild to chronic bacterial 
infections. Bacteria are capable to survive after exposure to antibiotics with multiple 
ways of adaptations, for instance, changing cell wall permeability, modify or change 
the original target cell, and produce lysozymes (Levy, 1998). Even though antibiotics 
are able to successfully retard bacterial reproduction, DNA transmission out of the 
dead bacteria remains possible through plasmids. This enables most of the resistance 
and virulence genes stored in horizontally mobile elements (HMEs) to be transferred 
out through conjugation, which allow gene transfer from one resistant bacterium to 
other bacteria, or what is even worse, possibly to eukaryotes (Heinemann, 1999). 
This secondary effect of antibiotics should be taken into serious consideration when 
it comes to the search of alternatives for combating resistance.  
The presence of resistance genes in one bacterium will not only be retained, 
but they will spread within a short period of time, leading to uncontrollable 
antibiotic-resistant bacteria population (WHO, 2013). Antibiotic-resistant bacteria 
started off as hospital-acquired infections, whereby only patients who are 
immunocompromised and stay in hospital for long terms would be exposed. For now, 
the evolution has moved to the global community due to the misuse and overuse of 
broad spectrum antibiotics by most of the medical practitioners, leading to 
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accelerated emergence of plasmid-borne antibiotic resistance bacteria (Svara and 
Rankin, 2011).  
Multidrug-resistant tuberculosis (MDR-TB) has been a major issue as the 
infection rates have been increasing distinctively with respect to its growing resistant 
strains towards isonizaid and rifampicin, especially with the increased amount of 
HIV and immune-compromised patients in the hospital facilities (Jacobs, 1994). 
According to World Health Organization (2012), an estimated total of 8.7 million 
people are infected with tuberculosis in 2011. A shocking result of 18.2% and 13.6% 
respectively of drug resistance rate for the age group of 0-14 years old and 15-24 
years old proved the importancy to overcome resistance (Jacobs, 1996). Another 
recent incident to be taken note is the multi-antibiotics resistant human pathogen 
Pseudomonas aeruginosa, which was found to be associated with fatal nosocomial 
infections in ICUs. Ozer et al. (2012) have studied intensively on patients who 
suffered from lower respiratory tract infection (LRTI) in intensive care unit (ICU) of 
Mustafa Kemal University Hospital and they have found out that 86% of them were 
determined to carry at least one resistant gene, with NfxB gene being the most 
common resistant gene found which causes resistant to Norfloxacin and 
Ciprofloxacin (Ozen et al., 2012). The examples listed are merely one among 
millions of them. With such, conventional antibiotics are said to be nearing the end 
of effectiveness. 
Understanding the impact of the antibiotic-resistant bacteria occurrence to the 
world, it is essential to come up with new generation drugs to solve the problem. 
(Spratt, 1996). The creation of stronger antibiotics has also proven to be an 
unsuccessful alternative as it only causes increased rapid emergence of stronger 
antibiotic-resistant bacteria. This crisis of modern medicine has to be controlled, or 
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even reduced significantly with a novel cure for bacterial infections, especially those 
with virulence and resistance genes. Various methods have been implemented to 
combat the problem, such as antibiotic heterogeneity (Sandiumenge et al, 2006.), but 
none of them found to be a permanent solution. There is an urgent need to come out 
with a novel cure against multidrug-resistant bacteria, in an unconventional modes of 
action, opening up for possibility to give desirable anti-infective properties without 
causing antibiotic resistance. 
2.2 Pseudomonas aeruginosa as pathogen 
 According to Centers for Disease Control (CDC), approximately 1.7 million 
patients suffer from hospital-acquired infections annually, which are the fourth 
leading cause of death in the United States (Klevens et al., 2007). There are various 
types of bacteria present in the hospital environment which are pathogenic enough to 
cause hospital-acquired infections especially in immunocompromised patients. P. 
aeruginosa, the rod-shaped gram negative bacterium, is the fifth most frequently 
isolated nosocomial pathogen, in which there is a 71% increase in resistance rates 
within 6 years timeframe (NNIS system, 2004). The blue-green colored bacteria is 
one of the most prevalent opportunistic pathogen, which responsible for 14-16% of 
nosocomial pneumonia, 7-11% of urinary tract infections, 8% of surgical site 
infections and 2-6% of bloodstream infections (Emori et al., 1993; NNIS system, 
1998).  
Typically, P. aeruginosa is found in moist environment, for instance, in soil, 
water, fruits, vegetables, flowers and all sorts of solutions. In hospital environment, 
the well adapted pathogen may be spread through healthcare personnel, equipments, 
devices and solutions in hospitals. Patients with prolonged usage of breathing 
8 
 
machines, catheters and patients with wounds from surgery and from burns are 
potentially at high risk for Pseudomonas infections (DiazGranados et al., 2009; CDC, 
2013). Along the way, the pathogen is capable to accommodate environmental 
variation via transformation, transduction and conjugation for genetic information 
exchange to acquire resistance genes on mobile genetic elements. With the single and 
supercoiled chromosome in P. aeruginosa, the bacterium carries chromosome-
mobilizing plasmids encoded for β-lactamase production (Fick, 1993). It breaks 
down polycyclic aromatic hydrocarbons, hence it became resistance towards β-
lactam and quinolone antibiotics such as tobramycin, making it one of the toughest 
pathogen to counterattack (Lister et al., 2009).  
 Many researchers and scientists have been working on to halt the propagation 
of this opportunistic pathogen with various ways, since antibiotic does not seem to 
work well with multi-resistant P. aeruginosa. The pathogenesis of P. aeruginosa 
works via cell association as well as secretion of virulence factors. It is capable to 
make use of flagella to deliver effector proteins into the host cells and 
lipopolysaccharides that are capable to suppress immune system of the host and 
establish persistent infections (Lister et al., 2009). As for virulence factors, the 
pathogen secretes elastase and protease, which both lead to the degradation of host 
proteins such as elastin, collagen and transferrins. Besides, P. aeruginosa possesses 
type IV pilli, exotoxin A, alkaline protease, phospholipase C and type III secretion 
system, whereby all of them also play major roles in bacterial pathogenicity (Salyers 
and Whitt, 1998; Wareham et al., 2005).  
In this study, clinical isolate of P. aeruginosa from a human burn patient, 
strain PA14 has been selected due to its capability to infect a large variety of hosts, 
with Caenorhabditis elegans being one of them. Pathogenic interaction between P. 
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aeruginosa strain PA14 and genetically tractable host C. elegans will serve as a 
model system to understand the mechanism behind mammalian pathogenesis, which 
involves host defence mechanism and bacterial virulence factors (Tan et al., 1999). 
Interestingly, the virulence factors required for PA14 to infect C. elegans is 
evolutionary conserved, in which similar set of virulence factors is capable of 
infecting plants, insects and vertebrates as well (Rahme et al., 1995). With the hope 
of fighting this superbug, it is essential to form a strong defense against P. 
aeruginosa to halt the continue resistance towards broad spectrum antibiotics by 
studying its pathogenesis in molecular level, as well as find out effective approaches 
to counterattack it.    
2.3 The discovery of anti-infective compounds 
With the continuous increasing microbial resistance, it is crucial to control 
and minimize the spread, especially for those multi-resistant pathogens. Researchers 
and scientists have been focusing on dose, duration, pharmacokinetic/ 
pharmacodynamic (PK/PD) principles to provide new insight in designing the 
appropriate dosage to maximize the clinical cure of antimicrobial drugs, at the same 
time reduce toxicity and also resistance (Mouton et al., 2011; Alvan et al., 2011). 
Sadly, this alternative only provides temporary resistance control and more research 
has to be done in understanding the mechanism of emergence, into the spread of 
resistant as well as into drug exposure-resistance relationships (Theuretzbacher and 
Mouton, 2011). Numerous researches on drug discovery have decided to approach 
this crisis with antibiotics with multiple mode of actions in one, or counterattack the 
pathogens another way round instead of using the traditional approach of drug 
discovery on developing antibiotics, such as cell wall biosynthesis disruption, protein 
synthesis inhibition, a halt in DNA replication and reducing virulence factors of the 
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pathogen (Monaghan and Barrett, 2006). There are new findings reported 
consistently on combating this problem with various approaches.  
Instead of eliminating the invading pathogens directly like what usual 
antimicrobial drugs do, the active ingredients in anti-infective agents attack the 
pathogens through different mode of actions: in which some prevent pathogen from 
adhering to host tissues (Zopf and Roth, 1996), some work by reducing pathogen’s 
virulence factor (Marra, 2004) and some tap on modulating the host’s immune 
system to counteract with the pathogen. As it is impossible to put a halt in the usage 
of antibiotics, the creation of novel anti-infective agents plays an important role in 
preventing us from falling back to pre-antibiotic era. There are no easy ways to 
combat resistance, multiple counter measures and actions are necessary on all 
different aspects in this long term war, especially in terms of knowledge/information 
exchange, coordination and cooperation throughout the whole science community.  
An interesting approach proposed by Zopf and Roth (1996) will be the use of 
soluble oligosaccharides as anti-infective agents, by developing anti-adhesive 
therapeutic agents in the form of small (~1kDa) non-immunogenic human 
oligosaccharide component to prevent microbial adhesin from binding to the specific 
carbohydrate receptor on the host (Wick et al., 1991). This strategy is less likely to 
cause resistance as it works mechanically, whereby non-adherent microorganisms are 
easily cleared through normal functioning human mucosal surfaces. Marra (2004) 
proposed another novel molecular approach in targeting virulence genes of the 
specific attacking pathogen. Signature-tagged mutagenesis, in-vivo expression 
technology (IVET), differential fluorescence induction (DFI) technology and other 
genomics and micro-array technology are applied to screen for essential virulence 
genes to cause an infection and monitor both their in vivo expression level and 
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pattern whereby the products are involved in the biosynthesis and nutrient source of 
the pathogen of interest (Saenz and Dehio, 2005; Angelichio and Camilli, 2002; 
Mahan et al., 1995).  
Scientists have also been searching for compounds which possess 
antimicrobial or immunomodulatory properties without a similar structural motif and 
mode of actions with existing drugs to combat bacteria resistance from both 
terrestrial and marine natural products. The results are promising as compared to 
synthetic libraries, whereby there is an increase in ten-fold of hit rate. Purple 
coneflower, Echinacea angustifolia is known to be plant immunostimulants, where 
cichoric acid, polysaccharides and alkylamides are thought to contribute to stimulate 
the phagocytic activity of neutrophils and macrophages in vitro and in vivo (Parnham 
and Verbanac, 2011). Methanolic extract of marine sponge Spongosorites 
halichondriodes, which contains glycospingolipids are thought to possess 
immunomodulating activity whereby it reduces the total white blood cell count and 
prevents myelosuppression in cyclophosphamide drug treated rats (Kumar et al., 
2012). Various new chemical entities are mostly found in active secondary 
metabolites of natural products available in both terrestrial and marine environment, 
often with a very complicated scaffold and excellent biological potency.  
 
2.4 Host-pathogen interaction 
Every living organism, let it be plants, invertebrates or vertebrates, all of 
them utilizes innate immunity to repel infectious agents. It is the first line of defense 
against infection, whereby the organism undergoes three main responses: pathogen 
recognition, immune signaling and protective effecter responses; in which it will 
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only then mobilizes adaptive immune responses, provided if the organism has one 
(Gravato-Nobre and Hodgkin, 2005). Studying the mode of action on pathogen 
invasion through both host and pathogen perspectives is of best interest for the 
immunologists and researchers to understand the underlying mechanism of innate 
immunity that is most likely conserved among all living organisms (Aballay and 
Ausubel, 2002).  
Besides highly conserved innate immunity across phylogeny, Taylor et al 
(2001) also show that out of 1415 species of pathogen that is able to infect human, 61% 
of them has the capability to be transmitted between humans and animals. In other 
words, it indicates the ability of using vertebrates to facilitate the understanding of 
innate host defence mechanisms. There are several ways on studying host-pathogen 
interactions, which often complements with animal testing to observe the severity of 
the infections at whole organism level. The ethical concerns on the animal welfare in 
science research have shifted the study to search for model organisms of similar 
ancient evolutionary origins and conserved signaling mechanisms of humans’ innate 
immune system.  
The extensive studies have revealed interesting findings, whereby there are 
several genetically tractable model organisms available to conduct host-pathogen 
interactions study, namely Arabidopsis thaliana (Schlaich, 2011), Drosophila 
melanogaster (Limer et al., 2011), Danio rerio (Trede et al., 2004) and 
Caenorhabditis elegans (Tan et al., 1999). All of them contain 60-80% common 
mechanisms of innate immunity compared to mammals, which includes similar 
universal defense genes and biochemical pathways on controlling gene expression 
upon the increase of infection. Hence, it has been widely applied on investigating 
host-pathogen interactions to give a new level of insights of the pathways in both the 
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host and pathogen, subsequently lead to the development of possible cure to certain 
diseases.  
 
Upon understanding how host-pathogen interactions work, a simple non-
vertebrate host, Caenorhabditis elegans, is used to address the pathogenicity 
question that involves host-pathogen interaction of C. elegans upon infection of 
human ubiquitous opportunistic pathogen, P. aeruginosa. The high degree of 
conservation between the innate immune system of C. elegans and human has made 
it possible for the nematode worm to be coupled with human ubiquitous pathogen P. 
aeruginosa, which has the capability to cause an infection in the nematode worm, to 
identify the universal virulence factors and to study the conserved mechanism of 
innate immunity (Tan et al., 1999; Ewbank, 2002).  
2.4.1 Caenorhabditis elegans as host 
Caenorhabditis elegans is a free-living soil nematode which grows up to 
1mm in length and it feeds on various bacteria present in its natural habitat. The 
population of C. elegans is predominantly hermaphrodite, with only 0.1% of them 
being male in wild-type populations (refer Figure 2.1). A self-fertilized 
hermaphroditic nematode worm produces up to 300 progeny, while it can produce up 
to 1000 progeny when a hermaphrodite is male-fertilized. Every adult C. elegans 
contains 959 somatic cells and they are similar in position and identity between 
individuals (Strange, 2010). A healthy adult nematode worm has an average life span 
of 3-4 weeks in 25
o
C upon optimal laboratory conditions, where it only needs 12 
hours to undergo a full cycle of embryogenesis with another 28 hours for 
postembryonic development from L1-L4, as per shown in Figure 2.2 (Altun and Hall, 
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2006). When there is insufficient food supply, C. elegans produces dauer hormone, 
whereby it enters dauer larvae stage which has structural, behavioral and metabolic 
adaptations to resist stress and starvation for up to 4 months (Golden and Riddle, 
1982; Hu, 2007). Dauer larvae will resume back to normal development stage when 
food becomes available.  
The unique features of C. elegans has attracted attention from Sydney Brenner and 
he adopted it as a laboratory model. The founder of C. elegans, Brenner initiates the 
study of the nematode worm for developmental and behavioural study in the early 
sixties, whereby the work won him and his colleagues, John Sulston and H. Robert 
Horvitz the Nobel Prize in Physiology or Medicine in 2002 (Nobelprize.org, n.d.). 
The model organism he found is capable of being used as a genetic analysis tool to 
elucidate different types of molecular mechanisms, with great experimental 
advantages. C. elegans can be easily cultured on nematode growth medium (NGM), 
seed with Escherichia coli OP50 as food source (Brenner, 1974). The development 
of the nematode worm can easily be manipulated by the incubation temperature, 
which is advantageous for experimental purposes. As the main infection site for C. 
elegans is the intestine, infection can easily be triggered by changing the food source 
to the pathogen of choice. The body transparency of C. elegans enables physical 
observation of the stimuli effect on the nematode directly under the microscope 
without the need of sacrificing it, such as the monitoring of animal survival, 
locomotion, pharyngeal pumping rate and so on. The body transparency of the 
worms allow GFP reporters to be present in the living animals for in vivo monitoring 
studies at the cellular and intracellular level (Ewbank, 2002).  
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Figure 2.1. The hermaphrodite and male C. elegans. Schematic (left) and 
microscopic (right) images of both hermaphrodite (A) and male (B) C. elegans. The 
distinctive features for hermaphrodite worms would be the presence of uterus, eggs 
and vulva while the male worms possess fan shaped tail.  
(Altun and Hall, 2006) 
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Figure 2.2. The life cycle of C. elegans. The nematode worm goes through 
embryogenesis, which then proceeds to larval stage development (L1-L4) to be a 
fertile adult. The larval development can be bypassed to form dauer larvae when 
food resource is limited, which they will then continue with the life cycle when 
conditions are favorable.  
(Altun and Hall, 2006) 
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The C. elegans Genome Sequencing Consortium has completed the genome 
sequencing project, which contains 100Mb in total and encodes for more than 19099 
proteins (C. elegans Sequencing Consortium, 1998). Being the first multicellular 
organism to have its genome fully sequenced, C. elegans has been extensively 
researched to extrapolate the relationship between this model organism and human. 
The combination of good genetic maps, low cost and maintenance, easily 
visualization and efficient system for transgenic animals’ generation enables C. 
elegans to be selected as the model organism for pharmacological studies which then 
contributes large to a bigger picture.  
Tan (2002) have showed the ability of various human pathogens to infect 
multiple hosts, from invertebrates, plants to vertebrates. The huge similarities of 
bacterial virulence factors required for an occurrence of P. infection in mammals and 
for C. elegans killing has demonstrated the key features of conserved innate immune 
response. There are three different killing mechanisms of pathogens on nematode: 
toxin-mediated, intestinal infections and biofilm formation. When the food source of 
C. elegans is being replaced by candidate pathogens under particular culture 
conditions, the worms produce fast-acting nematicidal toxins and other diffusible 
factors. The toxin-mediated effect is termed as ‘fast killing’, where worms are killed 
within 4-24 hours. The examples of pathogen that can exert such killing mechanisms 
are Burkholderia multivorans (O’Quinn et al., 2001) and Bacillus thuringiensis 
(Marroquin et al., 2000). Some pathogens, for instance P. aeruginosa strain PA14 
(Tan et al., 1999), Salmonella enterica (Aballay et al., 2000), Enterococcus faecalis 
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(Garsin et al., 2001), can establish intestinal infections by colonizing the intestine of 
the worms and kill the animal over several days, termed as slow-killing.  
Another type of killing mechanism possess by bacteria Yersinia pestis and 
Yersinia pseudotuberculosis would be biofilm formation (Joshua et al., 2003). It is a 
widespread attribute to increase survival ability under stress (Costerton et al., 1995). 
The pathogen adheres to the surface region of the mouth and vulva to form biofilm, 
whereby the biofilm prevents the nematode from feeding. In the context of biofilms, 
P. aeruginosa remains as the most studied microbes (Costerton, 2001). The organism 
forms multicellular aggregates within the lungs of cystic fibrosis patients and 
surfaces of catheters (Deretic, 2000). Hence, it is crucial to determine the genes 
involved in the production of biofilm matrix to develop new therapeutic strategies 
(Friedman and Kolter, 2004).  
Upon understanding these killing mechanisms of pathogen to C. elegans, it 
expands the possibility of using the nematode worm to identify the underlying innate 
immune response which is evolutionarily conserved, as well as to determine the 
candidate universal virulence factors of these pathogens. The test system involving C. 
elegans is relatively simple, rapid and inexpensive as compared with the use of other 
vertebrate hosts (Kim, 2008). The pathogenicity of P. aeruginosa is of particular 
interest to be studied due to the society concerns towards occurrence of hospital-
acquired infections, whereby a solution in tackling both the host and pathogen all at 
once would be desirable.  
2.4.2 C. elegans as viable screening system for drug discovery  
 The added advantages of having highly conserved biochemical pathways and 
gene functions between C. elegans and human have gained confidence that this tiny 
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organism could be a viable screening assays for drug identification. As traditional in 
vitro and cell-based screening assays in drug discovery have possibilities of yielding 
toxic hit compounds or compounds with same mode of action with current known 
antibiotics, a unique approach of drug screenings through an environment that 
imitates infected human host is recommended by Moy and coworkers (2006). This is 
achieved by assaying the nematode, C. elegans infected with Enterococcus faecalis. 
From small-scale manual screening assay of 6,000 compounds to high-throughput 
screening of 37, 200 compounds, a total of 44 of them were found to promote the 
nematode survival upon E. faecalis infection. It has also been observed that the 
extracts acted differently on the pathogenic infection: some cure the bacterial 
infection in vivo without affecting the growth of pathogen, while some possess 
antimicrobial properties (Moy et al., 2006; Moy et al., 2009). Hence, it can be said 
that the use of live-animal infection model has added advantage in addressing novel 
compound identification of potential medical interest, and even the mechanism of 
action could be made known.  
 The contribution of live-animal infection model in drug screenings has 
enabled further advancement of the current paradigm in several key approaches. It 
directly assesses the drug efficacy and eliminates compounds that are toxic to host in 
the early stage of analysis, which would only possible when host-pathogen 
relationship presents. Unlike in vitro and cell-based assays, the drug target could also 
be known when it corrects a phenotype in mutant strains of C. elegans, giving 
information on where the molecule act upon, as well as the target of the molecule in 
a specific biochemical pathway (Segalat, 2009). In this study, the use of live-animal 
infection screening assay of C. elegans to search for potential anti-infective 
molecules in marine natural product against P. aeruginosa infection serves as a 
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powerful yet unique assay. It holds the potential of simultaneously identify the effect 
of marine natural product on both the pathogen virulence-related genes and host 
immune-related antimicrobial molecules, which then the findings reach an 
implication on the conserved bacterial pathogenesis from C. elegans to human 
(Mellies and Lawrence-Pine, 2010).  
2.5 Potential of natural product in drug development  
From a 30-year review of new drugs from 1981-2010, there are 71% of the 
1350 new approved drugs are from natural products, derived or molecularly inspired 
by natural products (Newman and Cragg, 2012). With this in mind, no doubt natural 
product, let it be from terrestrial or marine origins, will be the major player for drug 
development as there are higher hits on discovering new chemical entities from 
natural resources as compared to synthetic scaffold formulation, which are targeted 
on secondary metabolites in particular. Secondary metabolites are usually available 
in a particular group of living organisms, species or strain under specific 
environmental positions (Sarker et al., 2005). Interestingly, the exact biological 
functions of these small molecules with molecular weight less than 2000 atomic 
mass units are unknown, and are not strictly essential for the survival or the 
organisms. This raises many biological questions to further invest their potential 
benefits to mankind with endless possibilities (Lou, 2011). The scaffolds derived 
from natural resources are in such complex form that it is impossible to synthesize 
chemically without living organisms. This indicates the possibilities of utilizing the 
natural resources, as well as making a promising trend for upcoming plans on drug 
development (Claeson and Bohlin, 2012).  
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Nature has wide range of biodiversity for various supplies, such as food, 
medicine, skincare regimes, agricultural chemicals, cleaning products; you name it. 
They offer a very huge untapped reservoir of chemical compounds and metabolites 
which may contribute to beneficial usages back in ancient times (Singh and Barrett, 
2006). “Ebers Papyrus” is known to be the oldest record of ancient Egyptian 
medicine, which documented over 700 drugs back in 1500BC, and most of the drugs 
are originated from plant origin, for instance, the oils of Cedrus species, the resin of 
Commiphora myrrha and the juice of poppy seed Papaver somniferum (Newman et 
al, 2000). The record is further proven as there are several records from China and 
Mesopotamia which records over 1000 substances of plant origins, including Aloe 
vera and Boswellia caeteri (Zhong and Wan, 1999; Cragg et al., 2009).  
Since plants have been known to aid in treating various ailments, the search 
for potential new drugs begins with plants. E. Merck has successfully 
commercialized morphine in 1826, in which its pure form is isolated from opium 
poppy Papaver somniferum (Newman et al., 2000). For early discoveries, it can be 
seen that almost all of the new chemical entities found are from terrestrial origin. 
There are compounds with different pharmacological activities isolated from plants 
being reported consistently throughout all these years, including anti-bacterial (Kim 
et al, 2002; Medeiros et al, 2011), anti-cancer (Bardona et al., 2002; Shoeb et al., 
2006), anti-inflammatory (Chen et al., 2001; Ueda et al., 2002), anti-HIV (Qian-
Cutrone, 1996; Wang and Ng, 2001; Sung et al., 2005) and those with other 
therapeutic effects. Natural products of terrestrial origins, especially plants, have 
been constantly found to be the effective.  
Marine natural products only begin to catch the attention of the scientists in 
the mid-seventies and the development increases rapidly during 1980s when 
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Faulkner (1986) began a series of annual reviews about marine natural products. As 
marine environment comprises of half the global diversity, the contribution of natural 
products in searching for novel and active compounds has no boundary. Due to the 
completely different living conditions for marine organisms, unique structures are 
discovered continuously with the current technology. The continuous success in 
searching for novel compounds in marine natural products in the past 25 years have 
proven that refocusing the efforts on natural products is definitely the correct 
alternative (Hu et al., 2011).  
2.6 Marine natural products 
Marine environment is considered unexplored, with excellent potential of 
obtaining novel bioactive compounds from 225,000 described species of marine 
resources (World Register of Marine Species, 2014). Marine plants, bacteria and 
animals are living in very harsh and diverse natural habitats; some may live at 
shallow water with high temperature and sunlight penetration, while some live deep 
under the ocean with extremely high pressure, low temperature and without sunlight 
penetration (De Vries and Hall, 2004). The differences in marine ecosystem is so 
diverse that the production of biologically active compounds are found to have no 
scaffold similarities compared to those extracted from terrestrial organisms, and at 
the same time possess potent biological activity. As such, scientists and researchers 
are keen to move towards the ocean for novel drug discovery as the molecules 
obtained are molecularly unique with huge range of therapeutic properties (Newman 
and Cragg, 2007).  
The first reported discovery of bioactivity from marine resources was 
nucleosides spongothymidine and its derivative spongouridine from Caribbean 
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sponge Crypthitheca crypta in 1951 by Bergmann and Feeny. Two drugs are 
developed with the compounds found fifteen years later, which were anticancer agent 
Ara-C, for non-Hodgkin’s lymphoma and acute myelocytic leukemia, and antiviral 
compound Ara-A for herpes treatment (Bergmann and Fenny, 1951). Continuous 
investigation has been performed to gain access to the marine natural products, 
especially on those soft-bodied and/or slow moving marine organisms without a 
physical defense system. These creatures rely largely on producing toxic secondary 
metabolites as potential predators’ deterrence. The active compounds obtained from 
marine natural products are said to exhibit excellent therapeutic effect with unique 
yet targeted mode of actions. The results have been promising, with Ziconotide, the 
toxin from tropical snail, being the first marine peptidic drugs to be approved for 
chronic pain treatment which works as calcium channel blocker, interrupting pain 
signaling at the spinal cord level (Miljanich, 2004). 
There are a large variety of marine natural resources having the ability to 
produce secondary metabolites for different medicinal purposes. For instance, marine 
microbes have been heavily researched due to its unique ability to be semi-
synthesized to a sufficient amount of active pharmaceutical ingredients (API) to 
construct drugs for large commercial production (Piel, 2009; Gulder and Moore, 
2009). The structural similarity of compounds derived from marine invertebrates and 
in bacteria provide circumstantial evidences that they may be of bacterial origin. 
Table 2.1 shows the compounds isolated from marine invertebrates and their 
microbial symbionts that are currently undergoing clinical trials (Waters et al., 2010). 
Marizomib, a naturally-occurring salinosporamide isolated from marine 
actinomycete Salinospora tropica is working its way towards clinical trials. It has 
unique scaffold as well as unique β-lactone-γ-lactam proteasome inhibitor, which is 
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found to have novel mode of action for anticancer treatment (Potts et al., 2011). It 
thus can be known that marine microbes own a huge role in the drug development 
pipeline, and at the same time play a major role in biosynthesis of drug like 
molecules for drug construction.  
Marine plants such as seaweed and algae have also been reported to contain 
unique chemical structures with active bio-activity for human health improvement, 
often being used as functional food ingredients. For instance, the production of 
karlotoxins by dinoflagellate K. veneficum is capable of imitating high density 
lipoprotein (HDL) in human body to increase the transport rate of cholesterol back to 
liver for excretion, which will significantly reduce cholesterol level (Pandey and 
Sassetti, 2008). Another successful study done by Lin and coworkers (2010) have 
isolated four new bromophycolides (R,S,T and U), with all of them exhibit 
cytotoxicity against 12 selected human breast, colon, prostate, ovarian, lung and 
leukemia cancerous cell lines of while Bromophycolide S also show submicromolar 
activity with IC50 value of 0.9μM against human malarial parasite Plasmodium 
falciparum.  
Marine invertebrates are also one of the major contributor in producing potent 
secondary metabolites, in which its pharmacological activity includes anticancer, 
antiviral, antibacterial, antifouling and anti-inflammatory activities as shown in Table 
2.1 (Hu et al., 2011). There are five main taxonomic group for invertebrates, which 
includes Porifera, Cnidaria, Mollusca, Arthropoda, Echinodermata and other minor 
phyla. As most of the marine invertebrates are soft-bodied without physical defense 
system, usually they will initiate chemical defense mechanisms such as synthesis of 
defensins or toxin compounds which have the capability to instill fear to predators, 
maintain a safe distance from competitors and immobilize their prey. Hence, they 
